Expediting MIDD evidence generation to support quizartinib approval in newly diagnosed AML patients PAGE 33 (2025) Abstr 11445 Glatard A, Mezzalana E, Zheng M, Bergstrand M, Smania G. ConferenceMIDDOncologyPhase IIIProgram strategies and efficienciesRegulatory interactions Pharmetheus Affiliates Senior Director, MIDD Consultant Anaïs Glatard See bio Senior Director, MIDD Consultant Enrica Mezzalana See bio Principal Director, MIDD Scientific Lead Martin Bergstrand See bio Principal Director, MIDD Consultant Giovanni Smania See bio
